The Real-World Impact of Long-Acting Injectable Cabotegravir-Rilpivirine on Weight and Renal Function

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2025 Mar 5

PMID 40041628

Authors

Lukas McNaboe

Alvaro Ayala

Julia Kostka

Dorothy Wakefield

Lisa Chirch

Affiliations

Soon will be listed here.

Abstract

Despite the continued advancement in the efficacy and convenience of antiretroviral therapy (ART), counseling patients about the metabolic side effects of medications remains an integral task for clinicians. This retrospective study examines changes in weight and renal function in patients receiving long-acting injectable cabotegravir-rilpivirine (LAI CAB/RPV) compared to oral regimens in a real-world setting. In this small set of patients, LAI CAB/RPV led to less weight gain compared to oral integrase inhibitor-based regimens. However, there was no significant change in the estimated glomerular filtration rate (eGFR) between patients who were started on LAI CAB/RPV and those who continued to receive oral regimens with or without tenofovir alafenamide (TAF).

References

Domingo P, Villarroya F, Giralt M, Domingo J . Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV. Int J Obes (Lond). 2020; 44(9):1970-1973. PMC: 7445112. DOI: 10.1038/s41366-020-0551-5. View

Wilkinson D, Piasecki M, Atherton P . The age-related loss of skeletal muscle mass and function: Measurement and physiology of muscle fibre atrophy and muscle fibre loss in humans. Ageing Res Rev. 2018; 47:123-132. PMC: 6202460. DOI: 10.1016/j.arr.2018.07.005. View

Diez-Domingo J, Martin I, Sanz A, Lopez A, Martinez C, Boronat C . Rotavirus gastroenteritis among children under five years of age in Valencia, Spain. Pediatr Infect Dis J. 2006; 25(5):455-7. DOI: 10.1097/01.inf.0000217378.30444.21. View

Ramgopal M, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S . Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a.... Lancet HIV. 2023; 10(9):e566-e577. DOI: 10.1016/S2352-3018(23)00136-4. View

Grabar S, Potard V, Piroth L, Abgrall S, Bernard L, Allavena C . Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort. J Antimicrob Chemother. 2023; 78(3):757-768. DOI: 10.1093/jac/dkad007. View

Venter W, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M . Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019; 381(9):803-815. DOI: 10.1056/NEJMoa1902824. View

Goldberg R, Kania A, Michienzi S, Patel M, Badowski M . Weight Gain in Incarcerated Individuals Living With HIV After Switching to Integrase Strand Inhibitor-Based Therapy. J Int Assoc Provid AIDS Care. 2021; 20:2325958221996860. PMC: 7917853. DOI: 10.1177/2325958221996860. View

Tan D, Antinori A, Eu B, Galindo Puerto M, Kinder C, Sweet D . Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. J Acquir Immune Defic Syndr. 2024; 98(4):401-409. PMC: 11841724. DOI: 10.1097/QAI.0000000000003584. View

McMahon C, Trevaskis J, Carter C, Holsapple K, White K, Das M . Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight. PLoS One. 2020; 15(2):e0229617. PMC: 7048285. DOI: 10.1371/journal.pone.0229617. View

10.

Landovitz R, Zangeneh S, Chau G, Grinsztejn B, Eron J, Dawood H . Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077. Clin Infect Dis. 2019; 70(2):319-322. PMC: 6938971. DOI: 10.1093/cid/ciz439. View

11.

Wood B, Huhn G . Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?. Open Forum Infect Dis. 2021; 8(12):ofab542. PMC: 8643706. DOI: 10.1093/ofid/ofab542. View

12.

Sax P, Erlandson K, Lake J, McComsey G, Orkin C, Esser S . Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2019; 71(6):1379-1389. PMC: 7486849. DOI: 10.1093/cid/ciz999. View

13.

Wassner C, Bradley N, Lee Y . A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. J Int Assoc Provid AIDS Care. 2020; 19:2325958220919231. PMC: 7163232. DOI: 10.1177/2325958220919231. View

14.

Llibre J, Brites C, Cheng C, Osiyemi O, Galera C, Hocqueloux L . Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the.... Clin Infect Dis. 2022; 76(4):720-729. PMC: 10021070. DOI: 10.1093/cid/ciac130. View

15.

Vakili S, Paneru B, Guerrier C, Miller J, Baumrin E, Forrestel A . Altered adipose tissue macrophage populations in people with HIV on integrase inhibitor-containing antiretroviral therapy. AIDS. 2022; 36(11):1493-1500. PMC: 9391287. DOI: 10.1097/QAD.0000000000003278. View